Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen    BIIB

BIOGEN (BIIB)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Biogen Idec Inc. : Biogen Sees Positive Results From First Year of MS Treatment Study

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/20/2013 | 01:06pm CEST
   By Saabira Chaudhuri 
 

Biogen Idec Inc. (BIIB) said it has seen positive results from the first year of a two-year late-stage study of its investigational candidate for a type of multiple sclerosis.

Biogen said results from its two-year pivotal Phase 3 "Advance" study of Plegridy, its investigational candidate for relapsing-remitting multiple sclerosis dosed once every two weeks or every four weeks, indicate that Plegridy significantly reduced multiple sclerosis disease activity, including relapses, disability progression and brain lesions, compared with placebo at one year.

"These full first-year results provide a more complete picture of Plegridy and its positive effects on the reduction of relapse, disability progression and lesion development," said Peter Calabresi, director at the Johns Hopkins Multiple Sclerosis Center. "These data suggest that, if approved, Plegridy may offer the benefit of a less frequent dosing schedule, which would be a meaningful advance for people living with multiple sclerosis."

Plegridy--also called peginterferon beta-1a--met the primary endpoint of reducing annualized relapse rate at one year by 36% compared with placebo. It also met its secondary endpoint, reducing the proportion of patients who relapsed by 39% compared with placebo. Additionally, it significantly reduced the number of gadolinium-enhancing lesions by 86% compared with placebo.

Biogen described Plegridy as a new molecular entity in which interferon beta-1a is pegylated to extend its half-life and prolong its exposure in the body, enabling study of a less-frequent dosing schedule. The investigational drug candidate is a member of the interferon class of treatments and, if approved, would be a new addition to this class, which often is used as a first-line treatment for multiple sclerosis.

The latest announcement comes after, in January, Biogen said data from a late-stage trial of Plegridy were positive. At the time, Biogen said the study's primary endpoint was met for both the two-week and four-week dose regimens. Results showed that Plegridy also met the secondary endpoints. It noted that with both dose regimens studied the risk-benefit profile of Plegridy appears to be favorable.

Also in January, Biogen reported its fourth-quarter earnings fell 2.7% as the biotechnology company's preparations to launch a new drug for multiple sclerosis increased expenses and masked revenue growth from its existing multiple sclerosis treatment.

Shares closed Tuesday at $175.61 and were inactive in recent premarket trading. The stock has risen 47% in the past 12 months.

Write to Saabira Chaudhuri at [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIOGEN
05/24BIOGEN : to Present at the Bernstein 34th Annual Strategic Decisions Conference
AQ
05/21BIOGEN : to Present at the UBS Global Healthcare Conference
AQ
05/21J&J discontinuing AD trials of BACE1 inhibitor
AQ
05/17BIOGEN : New Organic Research Findings from Biogen Described (Crystallization of..
AQ
05/11Biogen and American Express rise; Symantec plunges
AQ
05/10BIOGEN : New Amyloid Data Have Been Reported by Investigators at Biogen (Structu..
AQ
05/10BIOGEN : and Neurimmune Announce Option Exercise for Alzheimer's Disease Investi..
AQ
05/10BIOGEN : Reports from Biogen Highlight Recent Findings in Biotechnology (Determi..
AQ
05/10BIOGEN : Study Results from Biogen Provide New Insights into Antibodies (Leverag..
AQ
05/07BIOGEN : Celebrates 40 Years as a Pioneer in Neuroscience
BU
More news
News from SeekingAlpha
05/23Trump set to sign "right to try" bill; biotechs rally 
05/23Is Celgene's Stock A Buy The Dip Opportunity? 
05/22CORE BIOTECH BUYS #16 : Taking Advantage Of Weakness To Add To Conviction Ideas 
05/21A Quantitative System To Invest In Quality Stocks 
05/18J&J bails on Alzheimer's candidate atabecestat on toxicity issues 
Financials ($)
Sales 2018 12 953 M
EBIT 2018 6 645 M
Net income 2018 4 519 M
Debt 2018 1 758 M
Yield 2018 -
P/E ratio 2018 13,33
P/E ratio 2019 12,24
EV / Sales 2018 4,80x
EV / Sales 2019 4,21x
Capitalization 60 393 M
Chart BIOGEN
Duration : Period :
Biogen Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Technical analysis trends BIOGEN
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 350 $
Spread / Average Target 22%
EPS Revisions
Managers
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Jeffrey D. Capello Chief Financial Officer & Executive Vice President
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Michael D. Ehlers Executive VP-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN-10.16%60 393
CSL LIMITED0.00%62 841
ALEXION PHARMACEUTICALS-1.22%26 197
GRIFOLS1.78%18 199
BIOMARIN PHARMACEUTICAL-0.80%16 344
CHONGQING ZHIFEI BIOLOGICAL PRDCT CO LTD--.--%12 519